{
  "id": 7526120,
  "title": "Montana’s experimental treatment law hands a VC the keys",
  "url": "https://urgent.news/2026/09/15/montanas-experimental-treatment-law-hands-a-vc-the-keys",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-15T09:45:01.000Z",
  "source": {
    "name": "Business Insider",
    "slug": "business-insider",
    "url": "https://www.businessinsider.com/montana-right-to-try-prospera-biotech-experimental-treatment-anzinger-2026-9"
  },
  "original_language": "en",
  "account": "Montana's experimental treatment law, known as right-to-try, allows patients to access drugs not yet approved by the FDA. The biotech industry helped draft this law in hopes of creating a medical tourism hub. Now, a privately run board, overseen by a biotech investor named Niklas Anzinger, decides which treatments to offer. This has raised concerns about conflicts of interest. Last month, the board approved a treatment involving a daily antihistamine and a proprietary sound mix, not approved by the FDA. Anzinger's venture-capital fund, Infinita VC, has invested in longevity startups in Honduras. Critics, like Arthur Caplan, a former head of medical ethics at New York University, call it a risky endeavor, akin to a prediction market rather than medical research.",
  "summary": "Investors on the libertarian fringe of the biotech industry are making their dream of wide-ranging access to experimental drugs a reality in Montana.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}